IA
ELDN icon

IFS Advisors’s Eledon Pharmaceuticals ELDN Stock Holding History

IFS Advisors’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100
Closed -$339 – 181
2025
Q1 		$339 Hold
100
– – ﹤0.01% 189
2024
Q4 		$412 Buy
+100
New +$394 ﹤0.01% 178

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

IFS Advisors's ELDN Position: Q2 2025 in Review

IFS Advisors sold out of Eledon Pharmaceuticals (ELDN) in Q2 2025, closing a stake of 100 shares — an estimated $339 sold.

IFS Advisors first reported a position in ELDN in Q4 2024 and held it in 2 quarters. The position peaked at $412 in Q4 2024. 85 funds tracked by Wall St. Rank hold ELDN as of Q2 2025.

  • IFS Advisors reported no remaining Eledon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • IFS Advisors sold 100 Eledon Pharmaceuticals shares in Q2 2025, an estimated $339.
  • IFS Advisors first reported a position in Eledon Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • IFS Advisors's Eledon Pharmaceuticals position peaked at $412 in Q4 2024.
  • 85 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2025.

Based on IFS Advisors's 13F filing for Q2 2025, filed 22 Jul 2025.